J. R. White et al. / Tetrahedron Letters 51 (2010) 3913–3917
3917
Wiley-VCH: Weinheim, 2005; (c) Kotha, S.; Lahiri, K. Eur. J. Org. Chem. 2007,
1221–1236; (d) Stefani, H. A.; Cella, R.; Vieira, A. S. Tetrahedron 2007, 63, 3623–
3658; (e) Gillis, E. P.; Burke, M. D. J. Am. Chem. Soc. 2008, 130, 14084–14085.
6. Barder, T. E.; Walker, S. D.; Martinelli, J. R.; Buchwald, S. L. J. Am. Chem. Soc.
2005, 127, 4685–4696.
obtained of F-3d found it to be equally amenable to this type of
chemistry (compared with 3d; Table 2, entry 5). We therefore set
out to synthesise a proof-of-concept target, starting with the cou-
pling of F-1 with propiolic acid (2g), which gave the triazole-4-car-
boxylic acid 17 in 94% yield. Although we ideally aimed for a
protected secondary amide synthesised in parallel to F-1, our ini-
tial attempts, though not exhaustive, were problematic and we
therefore opted in this instance to incorporate a tertiary amide
after the CuAAC. Pleasingly, N,N-diethylamide 19 was obtained in
56% yield in an unoptimised one-pot procedure from 17. With this
final intermediate in hand we subjected it to reaction with 4d un-
der the same Suzuki coupling conditions as used previously for 3a;
obtaining our target compound 20, bearing a 3-pyridyl motif, in a
respectable 90% yield. 5H-rufinamide derivative 20 was thus syn-
thesised in a 47% overall yield in four unoptimised steps, starting
from 1.0 mmol of azido-boronate F-1.
In conclusion, we have demonstrated that azido-boronate esters
such as 1 have the potential to undergo sequential coupling reactions
in high overall yield. The isolation and storage of 1 makes positive
improvements to process safety by eliminating contamination from
the azide anion, which is dangerously incompatiblewith a widerange
of common solvents, metal salts and acids.8 Finally, the successful
synthesis of 20 demonstrates the potential these substrates possess
for diversity-oriented synthesis of drug-like molecules. We are cur-
rentlyinvestigatingalternativecoresandfurtherapplicationsofthese
privileged structures.
7. (a) Bedford, R. B.; Nakamura, M.; Gower, N. J.; Haddow, M. F.; Hall, M. A.; Huwe,
M.; Hashimoto, T.; Okopie, R. A. Tetrahedron Lett. 2009, 50, 6110–6111; (b)
Torborga, C.; Beller, M. Adv. Synth. Catal. 2009, 351, 3027–3043.
8. For selected discussions on the incompatibility, stability and safety of azides,
see Refs. 3a and 1b; Conrow, R. E.; Dean, W. D. Org. Process Res. Dev. 2008, 12,
1285–1286.
´
9. Fedorov, A. Yu.; Shchepalov, A. A.; Bolshakov, A. V.; Shavyrin, A. S.; Kurskii, Yu.
A.; Finet, J. P.; Zelentsov, S. V. Russ. Chem. Bull., Int. Ed. 2004, 53, 370–375.
10. Sviridov, S. I.; Vasil’ev, A. A.; Sergovskaya, N. L.; Chirskaya, M. V.; Shorshnev, S.
V. Tetrahedron 2006, 62, 2639–2647.
11. Molander, G. A.; Ham, J. Org. Lett. 2006, 8, 2767–2770.
12. Huang, J.; Macdonald, S. J. F.; Harrity, J. P. A. Chem. Commun. 2009, 436–438.
13. Huang, J.; Macdonald, S. J. F.; Cooper, A. W. J.; Fisher, G.; Harrity, J. P. A.
Tetrahedron Lett. 2009, 50, 5539–5541.
14. Naumov, M. I.; Nuchev, A. V.; Sitnikov, N. S.; Malysheva, Y. B.; Shavyrin, A. S.;
Beletskaya, I. P.; Gavryushin, A. E.; Combes, S.; Fedorov, A. Yu. Synthesis 2009,
1673–1682.
15. Cho, Y. A.; Kim, D.-S.; Ahn, H. R.; Canturk, B.; Molander, G. A.; Ham, J. Org. Lett.
2009, 11, 4330–4333.
16. Scrafton, D. K.; Taylor, J. E.; Mahon, M. F.; Fossey, J. S.; James, T. D. J. Org. Chem.
2008, 73, 2871–2874.
17. Loren, J. C.; Krasin´ ski, A.; Fokin, V. V.; Sharpless, K. B. Synlett 2005, 2847–2850.
18. (a) Jin, S.; Choudhary, G.; Cheng, Y.; Dai, C.; Li, M. Chem. Commun. 2009, 5251–
5253; (b) Significant binding should reduce the rate of substitution, which was
comparable when employing either 1 or 4-bromobenzyl bromide. 11B NMR
analysis was also consistent with this conclusion.
19. p-Tolylboronic acid (7) was synthesised as detailed, or purchased from Frontier
Scientific Europe, product code T6078; see Supplementary data for full details.
20. Abbenante, G.; Le, G. T.; Fairlie, D. P. Chem. Commun. 2007, 4501–4503.
21. After 3 h of irradiation (100 W Blak-Ray B100 UV lamp) the single-crystal X-ray
structure was unchanged, further details are available in the Supplementary
data.
Acknowledgements
22. (a) Párkányi, L.; Besenyei, G. J. Mol. Struct. 2004, 691, 97–106; (b) Chesterton, A.
K. S.; Jenkinson, S. F.; Jones, N. A.; Fleet, G. W. J.; Watkin, D. J. Acta Crystallogr.,
Sect. E 2006, 62, o2983–o2985.
23. Darses, S.; Genet, J.-P. Chem. Rev. 2008, 108, 288–325.
24. For use of TMS-acetylene in CuAAC reactions and in situ de-silylation of the
products, see: Fletcher, J. T.; Walz, S. E.; Keeney, M. E. Tetrahedron Lett. 2008,
49, 7030–7032.
We are grateful to the EPSRC for funding. Dr. Stephen Flower is
thanked for helpful discussions.
Supplementary data
25. For discussions on atom-economy and protecting groups, see: (a) Clark, J. H.
Green Chem. 1999, 1–8; (b) Baran, P. S.; Maimone, T. J.; Richter, J. M. Nature
2007, 446, 404–408.
26. Wu, L.-Y.; Xie, Y.-X.; Chen, Z.-S.; Niu, Y.-N.; Liang, Y.-M. Synlett 2009, 1453–
1456.
27. Though no particular efforts to scrub any hydroxides from the stream were
made, no significant detrimental effect on the boronate was observed. A similar
procedure was recently reported: Jiang, Y.; Kuang, C.; Yang, Q. Synlett 2009,
3163–3166.
Supplementary data (experimental procedures, compound
characterisation data, and X-ray crystal structure data for 1) asso-
ciated with this article can be found, in the online version, at
References and notes
28. Martin, R.; Buchwald, S. L. Acc. Chem. Res. 2008, 41, 1461–1473.
29. Acetylene (produced from CaC2 and H2O) was used to saturate the reaction
solution. The reaction was run for 1 h at 60 °C, cooled and the process repeated
once more. Full details are available in the Supplementary data.
30. For background discussion, see: (a) Tan, D. S. Nat. Chem. Biol. 2005, 1, 74–84;
For exemplary examples of the CuAAC in this context, see: (b) Manetsch, R.;
Krasinski, A.; Radic, Z.; Raushel, J.; Taylor, P.; Sharpless, K. B.; Kolb, H. C. J. Am.
Chem. Soc. 2004, 126, 12809–12818; (c) Krasinski, A.; Radic, Z.; Manetsch, R.;
Raushel, J.; Taylor, P.; Sharpless, K. B.; Kolb, H. C. J. Am. Chem. Soc. 2005, 127,
6686–6692.
1. (a) Cane, D. E.; Walsh, C. T.; Khosla, C. Science 1998, 282, 63–68; (b) Sharpless, K.
B.; Finn, M. G.; Kolb, H. C. Angew. Chem., Int. Ed. 2001, 40, 2004–2021; (c) Kolb,
H. C.; Sharpless, K. B. Drug Discovery Today 2003, 8, 1128–1137; (d) Boyle, P. M.;
Silver, P. A. J. R. Soc. Interface 2009, 6, S535–S546.
2. Trost, B. M. Science 1985, 227, 908–916.
3. (a) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless, K. B. Angew. Chem., Int.
Ed. 2002, 41, 2596–2599; (b) Tornoe, C. W.; Christensen, C.; Meldal, M. J. Org.
Chem. 2002, 67, 3057–3064.
4. (a) Lutz, J.-F. Angew. Chem., Int. Ed. 2007, 46, 1018–1025; (b) Moses, J. E.;
Moorhouse, A. D. Chem. Soc. Rev. 2007, 36, 1249–1262; (c) Meldal, M.; Tornøe,
C. W. Chem. Rev. 2008, 108, 2952–3015; (d) Sumerlin, B. S.; Vogt, A. P.
Macromolecules 2010, 43, 1–13.
31. See the discussion of aryl chlorides in: (a) Cai, C.; Rivera, N. R.; Balsells, J.;
Sidler, R. R.; McWilliams, J. C.; Shultz, C. S.; Sun, Y. Org. Lett. 2006, 8, 5161; (b)
Bunin, B. A. Drug Discovery Today 2003, 8, 823–826.
5. (a) Matteson, D. S. J. Organomet. Chem. 1999, 581, 51–65; (b)Boronic Acids—
Preparation, Applications in Organic Synthesis and Medicine; Hall, D. G., Ed.;
32. Wheless, J. W.; Vazquez, B. Epilepsy Curr. 2010, 10, 1–6.